


2020 ACC/AHA Guidelines for Aortic Regurgitation



<p>Class 1 Procedure is recommended</p> <p>Class 2a Reasonable to perform procedure</p> <p>Class 2b Procedure may be reasonable</p> <p>Harm In patients with isolated severe AR who have indications for SAVR and are candidates for surgery, TAVI should not be performed.</p>	<p>Stage A: At risk of AR Stage B: Progressive AR Stage C: Asymptomatic severe AR Stage D: Symptomatic AR</p>	<p>RVol: Regurgitation volume RF: Regurgitation fraction ERO: Effective regurgitation orifice LVEF: LV ejection fraction LVESD: LV end systolic dimension LVESD: LV end diastolic dimension</p>
---	--	--

 : Changes from 2014 AHA/ACC Guidelines for Aortic Regurgitation; see back side of page for details.



Summary of changes from 2014 ACC/AHA Guidelines for Aortic Regurgitation

Recommendations	2014	2020	Changes in 2020
Asymptomatic patients with chronic severe AR and LV systolic dysfunction (LVEF <50%) (Stage C2)	Class 1, B	Class 1, B-NR	Updated LVEF ≤55%
Asymptomatic patients with severe AR with normal LV systolic function (LVEF ≥50%) but with severe LV dilation (LVESD >50 mm, stage C2)	Class 2a, B	Class 2a, B-NR	LVEF ≥55%, LVESD > 25mm/m ²
Asymptomatic patients with severe AR and normal LV systolic function at rest (LVEF ≥50%, Stage C1) but with progressive severe LV dilatation (LVEDD >65 mm) if surgical risk is low	Class 2b, C	Class 2b, B-NR	LV systolic function at rest (LVEF >55%; Stage C1), progressive decline in LVEF to low-normal range (LVEF 55% to 60%)
In patients with isolated severe AR who have indications for SAVR and are candidates for surgery, TAVI should not be performed		Class 3, B-NR	New category added

Reference:

- Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Journal of the American College of Cardiology* (2021)Feb 2;77(4):e25-197.
- Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Journal of the American College of Cardiology* (2014)Jun10;63(22):e57-185.

The contents herein are meant for Registered Medical Practitioners only.

Edwards, Edwards Lifesciences and the stylized E logo are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.

©2023 Edwards Lifesciences Corporation. All rights reserved. PP_IND_SSH_20 V1.0

Registered Office: Edwards Lifesciences (India) Private Limited | 4th Floor, Commerz II, International Business Park, Oberoi Garden City, Off Western Express Highway, Goregaon (East), Mumbai - 400063 | Phone No: +91 22 61931301 | Email: customer_care_edwardsindia@edwards.com | edwards.com

